Cancer cell

Results: 3981



#Item
21

ASX ANNOUNCEMENT 14 October 2015 Cynata to Investigate Cell Therapy for Cancer in Major New Collaboration

Add to Reading List

Source URL: cynata.com

- Date: 2016-03-08 18:52:12
    22

    A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Stagg R,

    Add to Reading List

    Source URL: s3.amazonaws.com

    - Date: 2014-09-25 16:14:56
      23

      NOTCH3 Protein Expression and Outcome in Small Cell Lung Cancer (SCLC) and Therapeutic Targeting with Tarextumab (Anti-Notch 2/3)

      Add to Reading List

      Source URL: posters.omed.s3.amazonaws.com

      - Date: 2015-12-11 14:21:05
        24

        Targeting Notch/Delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) pathways by an anti-DLL4/Anti-VEGF bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency in

        Add to Reading List

        Source URL: posters.omed.s3.amazonaws.com

        - Date: 2015-06-12 10:36:45
          25

          Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain

          Add to Reading List

          Source URL: posters.omed.s3.amazonaws.com

          - Date: 2015-11-04 11:34:18
            26

            Phase 1b Trial of Tarextumab (OMP 59R5) (anti-Notch 2/3 antibody) in Combination with Etoposide and Cisplatin (EP) in Patients (pts) with Untreated Extensive-Stage Small-Cell Lung Cancer (ED-SCLC): PINNACLE Study M Cathe

            Add to Reading List

            Source URL: s3.amazonaws.com

            - Date: 2014-09-25 16:16:58
              27

              NOTCH3 Protein Expression and Outcome in Small Cell Lung Cancer (SCLC) and Therapeutic Targeting with Tarextumab (Anti-Notch 2/3)

              Add to Reading List

              Source URL: posters.omed.s3.amazonaws.com

              - Date: 2016-02-21 23:46:50
                28

                A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer Dose Level – mg/kg Median age (years)

                Add to Reading List

                Source URL: posters.omed.s3.amazonaws.com

                - Date: 2016-01-22 10:42:40
                  29

                  A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer 1Hidalgo Patient Demographics (n=47) DEM + GEM

                  Add to Reading List

                  Source URL: s3.amazonaws.com

                  - Date: 2014-09-25 16:14:56
                    30

                    Dual targeting of the DLL4 and VEGF pathways with a bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency Wan-Ching Yen, Marcus M. Fischer, Gretchen Argast, Breanna Wallace, Min Wan

                    Add to Reading List

                    Source URL: posters.omed.s3.amazonaws.com

                    - Date: 2015-11-04 11:34:26
                      UPDATE